Literature DB >> 7470619

Characteristics of the synergistic actions of platelet agonists.

E M Huang, T C Detwiler.   

Abstract

Platelets are activated by many different agonists that act synergistically. Since there is a characteristic pattern of responses to each agonist, and since there is a clear distinction between weak and strong agonists, understanding the nature of the synergism and its physiologic significance requires characterization of the pattern of responses to the synergistic action of the various agonists. Shape change, aggregation, and secretion of ATP by human platelets in citrated plasma were analyzed after activation by ADP, epinephrine, arachidonic acid, gamma-thrombin, or collagen, either singly or in pairs. The patterns of responses were characteristic of the agonist in higher concentration relative to its threshold concentration; if neither was clearly higher, the pattern of responses was intermediate between the responses characteristic of each agonist. No combination of weak agonists had the characteristics of a strong agonist. These results help define the extent to which platelet responses can be attributed to the synergistic actions of weak agonists.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7470619

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination.

Authors:  S E Akopov; E S Gabrielian
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Specific correction of impaired acid hydrolase secretion in storage pool-deficient platelets by adenosine diphosphate.

Authors:  B Lages; C A Dangelmaier; H Holmsen; H J Weiss
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

3.  The potentiation of adrenaline-induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects.

Authors:  N A Alarayyed; B R Graham; B N Prichard; C C Smith
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

4.  Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.

Authors:  Jeffrey S Berger; Richard C Becker; Cynthia Kuhn; Michael J Helms; Thomas L Ortel; Redford Williams
Journal:  Thromb Haemost       Date:  2012-12-06       Impact factor: 5.249

5.  Variations in circulating catecholamines fail to alter human platelet alpha-2-adrenergic receptor number or affinity for [3H]yohimbine or [3H]dihydroergocryptine.

Authors:  M A Pfeifer; K Ward; T Malpass; J Stratton; J Halter; M Evans; H Beiter; L A Harker; D Porte
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

6.  Activation of platelets by modified C-reactive protein.

Authors:  B A Fiedel; R M Simpson; H Gewurz
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

7.  Serum concentration of piroxicam and inhibition of platelet aggregation in patients with rheumatoid arthritis and M. Bechterew.

Authors:  R Koytchev; R G Alken; E Gromnica-Ihle
Journal:  Agents Actions       Date:  1994-11

8.  A Pilot Study on Probing of Imatinib Induced Platelet Dysfunction in Patients with Chronic Myeloid Leukemia-Chronic Phase and Absence of Associated Bleeding Manifestation: Trying to Solve an Enigma.

Authors:  Rajib De; Ranjini Chowdhury; Tuphan Kanti Dolai; Biswajit Bhar; Mohammad Mirazul Islam; Prantar Chakrabarty; Suryyani Deb
Journal:  Indian J Hematol Blood Transfus       Date:  2020-11-13       Impact factor: 0.900

Review 9.  Quality Assessment of Established and Emerging Blood Components for Transfusion.

Authors:  Jason P Acker; Denese C Marks; William P Sheffield
Journal:  J Blood Transfus       Date:  2016-12-14

10.  Human platelet activation by C3a and C3a des-arg.

Authors:  M J Polley; R L Nachman
Journal:  J Exp Med       Date:  1983-08-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.